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Primary sclerosing cholangitis (PSC) is a rare liver disease with high clinical burden and significant 
heterogeneity in outcome.  The UK-PSC risk scores(1), based upon a national observational 
cohort study of >1000 patients from across the UK, provide a robust evaluation of PSC risk for 
individual patients based on clinical predictors of outcome.
In recognition of the fact that early and late risk may be driven by different covariates, we 
applied a novel approach and have thus built stronger predictive models (defined as a c-statistic 
>0.8) for both short- and long-term PSC risk. Additionally, we have validated our models in 
separate national and internationally-derived cohorts.
Importantly, we provide a simple means of interpreting the UK-PSC risk score with low- and high- 
risk groups.  Furthermore, we directly compare its predictive power with two well-established 
risk scores; the Mayo score and AST-to-platelet ratio index (APRI), in the same external validation 
cohort, establishing superior predictive value of the UK-PSC risk scores.   Our work thus 
addresses some of the challenges raised by patients as priority areas for research.
We appreciate Dr Wang and colleagues for their correspondence.  As noted by Wang et al. our 
manuscript makes comment on the recently reported c-statistic (c=0.68) of the Amsterdam-
Oxford model (AOM)(2) in the introduction to our paper, but at no point do we draw direct 
comparison with it. 
With general agreement that strong models have a reported c-statistic >0.8, we read with 
interest that the AOM could have been improved (with higher c-statistic) if they had chosen to 
create a short- and long-term models as was reported in our manuscript. In this, they further 
support an argument that future PSC risk models may better serve the clinical and patient 
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It has been encouraging for both patients and clinicians that in recent years, several PSC risk 
prediction tools have been published, and it will take time for these to be evaluated and 
interrogated. The AOM score has been recently validated(3), and over time we look forward to 
the UK-PSC score being similarly tested. It was beyond the scope of our manuscript to compare 
and externally validate every existing PSC risk score. 
We remain encouraged by the interest in our work, and the field’s commitment to work together 
to overcome the challenges patients with PSC face.  We are therefore pleased by ongoing efforts 
for a meta-analysis of existing datasets including our data as well as, amongst others, the 
Amsterdam team’s data, This, we believe, will most effectively help patients and clinicians 
navigate a difficult and challenging disease. 
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